Breaking News Instant updates and real-time market news.

GE

General Electric

$24.39

-0.15 (-0.61%)

16:32
10/06/17
10/06
16:32
10/06/17
16:32

GE vice chair Beth Comstock to retire effective December 31, 2017

GE announced that Vice Chair Beth Comstock will retire from GE effective December 31, 2017, after 27 years of service. Beth Comstock will continue to lead GE Business Innovations through the end of the year.

GE General Electric
$24.39

-0.15 (-0.61%)

09/26/17
JEFF
09/26/17
NO CHANGE
Target $40
JEFF
Hold
GE launch to weight on Repligen's valuation, says Jefferies
GE Healthcare (GE), Repligen's largest customer, announced plans to launch a new Protein A resin in the first half of 2018 that will not utilize Repligen as the manufacturer of the associated protein A ligand, Jefferies analyst Brandon Couillard tells investors in a research note. Repligen shares are down 12%, or $5.10, to $38.12 in morning trading. While the near-term financial impact appears negligible to Repligen, the long-term implications are negative, Couillard contends. He believes GE's move to in-source protein A ligands "diminishes the value" of Repligen's "near-monopoly position" and could weigh on its "premium" multiple. The analyst has a Hold rating on Repligen with a $40 price target.
09/26/17
SPHN
09/26/17
NO CHANGE
Target $50
SPHN
Overweight
Stephens sees GE resin as niche, remains positive on Repligen
Stephens analyst Drew Jones says he's "not distracted" from his positive long-term outlook on Repligen (RGEN) after GE Healthcare (GE) announced plans to launch MabSelect resin, which does not use a Repligen Protein A ligand. This will be a niche resin that won't drive "meaningful" revenue for at least five-to-seven years, Jones tells investors in a research note. He adds that Repligen's revenue from GE will not be impacted due to long-term contracts. The analyst sees "no reason" to alter his Overweight stance on Repligen shares.
10/03/17
JANY
10/03/17
NO CHANGE
Target $47
JANY
Buy
Repligen overreaction to GE news a buying opportunity, says Janney Capital
Janney Capital analyst Paul Knight said he views the selloff in Repligen (RGEN) after GE (GE) announced a new resin as a "major overreaction", noting that Repligen was in dialogue with GE around being the third party manufacturer. He thinks Repligen is focused on building out its Direct product portfolio and GE would like to develop an added source in the event Repligen were to be acquired, he tells investors. The analyst, who said the launch of a new Larger Opus column and other products in 2018 provide visibility, keeps a Buy rating and $47 fair value estimate on Repligen shares.
10/05/17
MSCO
10/05/17
NO CHANGE
Target $25
MSCO
Equal Weight
General Electric likely to cut FY17 EPS view below $1.50, says Morgan Stanley
Morgan Stanley analyst Nigel Coe said he expects General Electric to lower its FY17 EPS guidance to below $1.50 per share from its currently stated view of $1.60-$1.70 when the company reports earnings on October 20. The analyst, who has $1.40 EPS forecast for the full year, also expects GE to reduce its $12B-$14B CFOA target to closer to $11B and sees scope for the buyback program to be scaled back. Coe, who is not certain if all of this is priced into the stock, is "tactically cautious" into the report and keeps an Equal Weight rating and $25 target price on GE shares.

TODAY'S FREE FLY STORIES

MLNX

Mellanox

07:44
02/22/18
02/22
07:44
02/22/18
07:44
Recommendations
Mellanox analyst commentary  »

Mellanox price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

RDHL

RedHill Biopharma

$6.26

0.05 (0.81%)

07:44
02/22/18
02/22
07:44
02/22/18
07:44
Earnings
RedHill Biopharma reports Q4 EPS (26c), consensus (60c) »

Reports Q4 revenue $2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

07:43
02/22/18
02/22
07:43
02/22/18
07:43
Conference/Events
JPMorgan to hold a conference »

Korea Conference will be…

HSC

Harsco

$16.75

0.45 (2.76%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Earnings
Breaking Earnings news story on Harsco »

Harsco sees FY18 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Conference/Events
Deutsche Bank to hold a conference »

Indonesia Corporate Days…

ROKU

Roku

$51.10

-0.08 (-0.16%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Recommendations
Roku analyst commentary  »

Roku price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 21

    Mar

HSC

Harsco

$16.75

0.45 (2.76%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Earnings
Breaking Earnings news story on Harsco »

Harsco sees Q1 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

AKBA

Akebia

$14.31

0.69 (5.07%)

, CRSP

Crispr Therapeutics

$41.16

-0.45 (-1.08%)

07:41
02/22/18
02/22
07:41
02/22/18
07:41
Conference/Events
RBC Capital to hold a conference »

Global Healthcare…

AKBA

Akebia

$14.31

0.69 (5.07%)

CRSP

Crispr Therapeutics

$41.16

-0.45 (-1.08%)

RDUS

Radius Health

$37.71

-0.51 (-1.33%)

TYME

Tyme Technologies

$3.37

-0.06 (-1.75%)

HCA

HCA Healthcare

$100.35

-0.65 (-0.64%)

ARAY

Accuray

MDRX

Allscripts

$13.57

0.335 (2.53%)

ABEO

Abeona Therapeutics

$11.70

0.1 (0.86%)

SGEN

Seattle Genetics

$54.11

-0.05 (-0.09%)

INSY

Insys Therapeutics

$7.93

0.34 (4.48%)

SPPI

Spectrum

$20.51

0.21 (1.03%)

SPH

Suburban Propane

$24.10

-0.2 (-0.82%)

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

DEPO

Depomed

$7.46

0.07 (0.95%)

KTWO

K2M Group

$19.09

-0.01 (-0.05%)

INOV

Inovalon

$11.68

-1.025 (-8.07%)

IMMU

Immunomedics

$16.38

0.16 (0.99%)

OVID

Ovid Therapeutics

$6.83

-0.2 (-2.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 11

    Mar

  • 14

    Mar

  • 01

    May

  • 03

    May

  • 22

    Feb

HSC

Harsco

$16.75

0.45 (2.76%)

07:40
02/22/18
02/22
07:40
02/22/18
07:40
Earnings
Harsco reports Q4 EPS ex-items 20c, consensus 14c »

Reports Q4 revenue $455M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

WPC

W.P. Carey

$59.53

-0.73 (-1.21%)

07:40
02/22/18
02/22
07:40
02/22/18
07:40
Hot Stocks
W.P. Carey enters into 18-year triple net lease with Astellas Institute »

W. P. Carey has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

07:40
02/22/18
02/22
07:40
02/22/18
07:40
General news
Fed's Quarles anticipates further gradual tightening »

Fed's Quarles…

ROCK

Gibraltar Industries

$31.75

0.35 (1.11%)

07:39
02/22/18
02/22
07:39
02/22/18
07:39
Earnings
Gibraltar Industries sees FY18 adjusted EPS $1.96-$2.08, consensus $1.81 »

Gibraltar is providing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$109.06

-1.92 (-1.73%)

07:39
02/22/18
02/22
07:39
02/22/18
07:39
Recommendations
Chevron analyst commentary  »

Chevron weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRC

Brady

$38.05

0.1 (0.26%)

07:38
02/22/18
02/22
07:38
02/22/18
07:38
Earnings
Brady reports Q2 EPS 8c, may not be compared to consensus 44c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ROCK

Gibraltar Industries

$31.75

0.35 (1.11%)

07:38
02/22/18
02/22
07:38
02/22/18
07:38
Earnings
Gibraltar Industries sees Q1 adjusted EPS 23c-28c, one est. 30c »

For Q1, the company is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCN

Welltower

$53.99

-0.81 (-1.48%)

07:37
02/22/18
02/22
07:37
02/22/18
07:37
Earnings
Welltower sees 2018 normalized FFO $3.95-$4.05, consensus $4.20 »

Expects average blended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ARWR

Arrowhead

$5.54

-0.11 (-1.95%)

07:36
02/22/18
02/22
07:36
02/22/18
07:36
Hot Stocks
Arrowhead receives regulatory clearance to begin Phase 1 study of ARO-AAT »

Arrowhead Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AABA

Altaba

$75.11

0.52 (0.70%)

07:36
02/22/18
02/22
07:36
02/22/18
07:36
Recommendations
Altaba analyst commentary  »

Altaba price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

HCN

Welltower

$53.99

-0.81 (-1.48%)

07:36
02/22/18
02/22
07:36
02/22/18
07:36
Earnings
Welltower reports Q4 normalized FFO $1.02, consensus $1.04 »

Reports Q4 revenue $1.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ROCK

Gibraltar Industries

$31.75

0.35 (1.11%)

07:35
02/22/18
02/22
07:35
02/22/18
07:35
Earnings
Gibraltar Industries reports Q4 adjusted EPS 41c, consensus 34c »

Reports Q4 revenue $258M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGEN

Repligen

$32.40

0.64 (2.02%)

07:35
02/22/18
02/22
07:35
02/22/18
07:35
Earnings
Repligen sees FY18 adjusted EPS 68c-72c, consensus 72c »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SRCL

Stericycle

$74.91

-0.31 (-0.41%)

07:35
02/22/18
02/22
07:35
02/22/18
07:35
Recommendations
Stericycle analyst commentary  »

Stericycle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAWS

Lawson Products

$23.80

0.3 (1.28%)

07:35
02/22/18
02/22
07:35
02/22/18
07:35
Earnings
Lawson reports Q4 EPS $2.21 including items, may not compare to two est. 16c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

C

Citi

$77.00

0.54 (0.71%)

, WFC

Wells Fargo

$59.73

-0.22 (-0.37%)

07:35
02/22/18
02/22
07:35
02/22/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

C

Citi

$77.00

0.54 (0.71%)

WFC

Wells Fargo

$59.73

-0.22 (-0.37%)

GM

General Motors

$40.56

-0.21 (-0.52%)

P

Pandora

$4.87

-0.46 (-8.63%)

ILG

ILG

$32.31

0.12 (0.37%)

BHGE

Baker Hughes

$26.76

0.32 (1.21%)

SLCA

U.S. Silica

$25.15

-5.6 (-18.21%)

RF

Regions Financial

$19.62

0.22 (1.13%)

SPB

Spectrum Brands

$100.87

-1.03 (-1.01%)

MNST

Monster Beverage

$65.02

0.42 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 13

    Mar

  • 15

    Mar

  • 30

    May

FCN

FTI Consulting

$43.18

-0.06 (-0.14%)

07:34
02/22/18
02/22
07:34
02/22/18
07:34
Earnings
FTI Consulting sees FY18 EPS $2.35-$2.65, consensus $2.25 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 05

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.